O’Mahony, DenisGudmundsson, AdalsteinnSoiza, Roy L.Petrovic, MirkoJose Cruz-Jentoft, AlfonsoCherubini, AntonioFordham, RichardByrne, StephenDahly, DarrenGallagher, PaulLavan, AmandaCurtin, DenisDalton, KieranCullinane, ShaneFlanagan, EvelynShiely, FrancesSamuelsson, ÓlafurSverrisdóttir, ÁstrósSubbarayan, SelvaraniVandaele, LoreMeireson, ElineMontero-Errasquín, BeatrizRexach-Cano, AuroraCorrea-Pérez, AndreaLozano-Montoya, IsabelVélez-Díaz-Pallarés, ManuelCerenzia, AnnaritaCorradi, SamantaSoledad Cotorruelo Ferreiro, MariaDimitri, FedericaMarinelli, PaoloMartelli, GaiaFong Soe Khioe, RebekahEustace, Joseph2021-06-012021-06-012020-07O’Mahony, D, Gudmundsson, A, Soiza, R L, Petrovic, M, Jose Cruz-Jentoft, A, Cherubini, A, Fordham, R, Byrne, S, Dahly, D, Gallagher, P, Lavan, A, Curtin, D, Dalton, K, Cullinane, S, Flanagan, E, Shiely, F, Samuelsson, Ó, Sverrisdóttir, Á, Subbarayan, S, Vandaele, L, Meireson, E, Montero-Errasquín, B, Rexach-Cano, A, Correa-Pérez, A, Lozano-Montoya, I, Vélez-Díaz-Pallarés, M, Cerenzia, A, Corradi, S, Soledad Cotorruelo Ferreiro, M, Dimitri, F, Marinelli, P, Martelli, G, Fong Soe Khioe, R & Eustace, J 2020, 'Prevention of Adverse Drug Reactions in Hospitalized Older Patients with Multi-morbidity and Polypharmacy : the SENATOR randomized controlled clinical trial', Age and Ageing, vol. 49, no. 4, pp. 605-614. https://doi.org/10.1093/ageing/afaa0720002-0729ORCID: /0000-0002-1397-4272/work/76608946ORCID: /0000-0002-0322-9244/work/171448018https://hdl.handle.net/2164/16596Acknowledgements: The trial was co-ordinated and the trial database was managed by the staff of the Health Research Board Clinical Research Facilities at University College Cork (HRB CRF-C). The authors wish to thank the patients and staff of the participating hospitals for their cooperation: (i) Cork University Hospital, Cork, Ireland. (ii) Ghent University Hospital, Ghent, Belgium. (iii) Hospital Universitario Ramón y Cajal, Madrid, Spain. (iv) Ospedali Riuniti, Ancona, Italy. (v) Landspitali University Hospital, Reykjavik, Iceland. (vi) Aberdeen Royal Infirmary, Aberdeen, Scotland. The authors wish to acknowledge the contributions of the staff of the following organizations in the SENATOR trial: (i) ClinInfo S.A, Lyons, France (Philippe Foerster). (ii) ARTTIC International Management Services, Munich, Germany (Dr Otilia Postea). (iii) Clanwilliam Health, Dublin, Ireland (Joseph McMullin, Anthony Maguire). (iv) HRB Clinical Research Facility— Cork, Cork, Ireland (Mary-Claire O’Regan, Aoife Harvey, Ruben Keane, Máire McCarthy, Sarah O’Meara). The authors further wish to acknowledge the oversight of the external Scientific Advisory Board (SAB) and the Ethics and Safety Review Group (ESRG) during the conduct of the SENATOR trial. SAB members included: Prof. Cillian Twomey (chairperson), Prof. Peter Crome, Dr Paul Jansen, Prof. Anne Spinewine, Prof. Jamie Coleman, Prof. Tischa van der Cammen and Prof. Jose M. Ribera-Casado. ESRG members included Prof. Shaun O’Keeffe (chairperson), Prof. Liam Plant and Robin Webster (older person advocate). Funding: This work was supported by the European Commission’s Seventh Framework Programme (FP7/2007– 2013) (grant number 305930) as part of the SENATOR project.102806699625684035engadverse drug reactionsolder peoplemulti-morbiditypolypharmacypreventionSTOPP/START criteriaSoftwaresoftwareRISK-FACTORSEVENTSADULTSINPATIENTSRIGHT TREATMENT CRITERIAINTERVENTIONSPHARMACISTSCREENING TOOLQUALITY-OF-LIFEELDERLY-PATIENTSAdverse drug reactionsPreventionPolypharmacyOlder peopleMulti-morbidityR MedicineGeriatrics and GerontologyAgeingEuropean Commission(FP7/2007-2013) (grant number 305930)RJournal article10.1093/ageing/afaa072http://www.scopus.com/inward/record.url?scp=85087530568&partnerID=8YFLogxK494